The global hydrocolloids market is valued at USD 12.67 billion in 2024, projected to grow to USD 13.44 billion in 2025, and further expand to USD 22.75 billion by 2034 at a CAGR of 6.04% (2025–2034).
Download the free sample and get the complete insights and forecasts report on this market @ https://www.towardshealthcare.com/download-sample/5592
Europe dominated the market in 2024, followed by Asia Pacific. Among products, gelatine held the major share in 2024, while xanthan gum is expected to grow significantly during the forecast period. By function, thickening agents dominated in 2024, and the gelling segment is projected to grow strongly.
Pharmaceutical applications had a notable market share in 2024, while personal care & cosmetics are anticipated to witness significant growth in coming years.
The market is shaped by key players such as DuPont, Palsgaard, Nexira, Ingredion, Kerry, BASF, Ashland, CP Kelco, Glanbia Nutritionals, Darling Ingredients, Tate & Lyle, Cargill, ADM, DSM, and others.
◉2024: USD 12.67 billion
◉2025: USD 13.44 billion
◉2034: USD 22.75 billion
◉CAGR (2025–2034): 6.04%
Dec 2024:
◉Ashok Matches & Timber Industries and Pioneer Jellice India (PJIP) made an open offer to acquire 1.84 million equity shares (26%) of India Gelatine & Chemicals (IGCL).
◉Offer price: ₹408.90 per share.
◉Deal value: ₹75 crore.
May 2024:
◉KSIDC and Nitta Gelatin Inc. Japan partnered to expand Nitta Gelatin India Ltd.
◉Expansion investment: ₹60 crore in Kerala.
◉Part of a larger ₹200 crore investment plan in Kerala announced by Nitta Gelatin.
◉Increasing use of hydrocolloids in nanocarriers for targeted and controlled drug delivery.
Benefits:
◉High biocompatibility and low toxicity.
◉Enhanced encapsulation efficiency.
◉Improved pharmacokinetics and drug stability.
◉Hydrocolloids used: guar gum, carrageenan, xanthan gum, gum arabic, pectin, etc.
◉Pharmaceutical industry: Significant adoption due to protective and stabilizing properties.
◉Personal care & cosmetics: Expected to grow at a notable CAGR due to rising consumer demand for natural and functional ingredients.
◉Research in hydrocolloid biotechnology is increasingly incorporating machine learning and AI tools.
◉AI algorithms are used to predict the physical and chemical properties of novel hydrocolloids by analyzing their molecular structures and compositions.
◉This predictive capability allows researchers to design tailor-made hydrocolloids for specific functions such as gelling, thickening, emulsifying, or drug delivery.
◉Traditional R&D processes for hydrocolloids require lengthy trial-and-error experimentation.
◉AI reduces costs and time by screening large molecular datasets virtually, identifying promising hydrocolloid candidates before physical synthesis.
◉This accelerates innovation in pharmaceutical excipients, wound-healing hydrogels, and personal care formulations.
◉One of the current challenges is the expansion of sustainable and cost-effective hydrocolloid production methods.
◉AI-based optimization models can reduce energy and water use in fermentation and extraction processes.
◉AI helps to forecast supply chain bottlenecks for raw materials like gelatin, guar gum, and carrageenan, making the industry more resilient.
◉Hydrocolloids are key in nanocarrier design for targeted and controlled drug release.
◉AI simulations predict how a hydrocolloid-based nanocarrier interacts with active pharmaceutical ingredients (APIs).
◉This ensures higher bioavailability, controlled release rates, and stability of drugs against degradation.
◉Hydrocolloids are widely used in dermatological patches and cosmetic formulations.
◉AI can analyze skin data and environmental factors to design hydrocolloid-based patches for acne, wound healing, and anti-aging.
◉Personalization becomes possible: AI-driven hydrocolloid products can be optimized for individual skin types and hydration needs.
◉Europe dominated the global hydrocolloids market in 2024 due to its robust R&D ecosystem and strict regulatory frameworks.
Consumer demand for clean-label and natural hydrocolloids supports industry growth.
Germany
◉Germany ranked as the third-largest exporter of gelatin in 2023 with USD 256 million exports.
◉Major export destinations: France (USD 26.3M), Japan (USD 22.7M), Italy (USD 21.7M), Switzerland (USD 18.7M), and the US (USD 17.1M).
◉German firms invest heavily in medical-grade and pharmaceutical-grade hydrocolloids.
2.1.4 United Kingdom
The UK ranked 13th globally in gelatin exports in 2023 with USD 62.7 million exports.
◉Exports required strict DEFRA facility listings, HACCP certification, and health approvals.
◉Top destinations included France (USD 34.2M), US (USD 19.2M), Canada (USD 1.7M), Ireland (USD 1.44M), and Italy (USD 1.32M).
◉The regulatory environment ensures high product quality and traceability, making UK hydrocolloids trusted in global markets.
◉Asia Pacific held the second-largest share in 2024, driven by pharmaceuticals, cosmetics, and food processing.
China
◉China’s gelatin exports reached USD 245 million in 2024 (ranked 721st product in exports).
◉Top destinations: US (USD 32.4M), India (USD 24.9M), South Korea (USD 19.6M), Japan (USD 18M), Vietnam (USD 16M).
◉Strong industrial capacity in China and Japan makes the region a major global supplier.
Japan
◉Japan was among the top gelatin exporters globally, with USD 139 million exports in 2023.
◉NITTA GELATIN INC. exported over 20,109 tons across 1,159 shipments.
◉Japan balances between being a major exporter and importer, reflecting its role as both a producer and consumer hub.
◉North America is projected to grow significantly during the forecast period.
◉Strong R&D capabilities and supply chains enhance adoption in pharmaceuticals and cosmetics.
United States
◉US exported USD 85.1 million worth of gelatin in 2024 (779th most exported product).
◉Major destinations: Canada (USD 32.8M), Mexico (USD 25.2M), Germany (USD 6.17M), India (USD 4.61M), Dominican Republic (USD 4.27M).
◉Export access to EU and UK depends on meeting facility listing requirements.
Canada
◉Health Canada strictly regulates hydrocolloids as emulsifiers, stabilizers, and thickeners.
◉Government invested USD 89.5 million over 5 years in the Canadian Drug Agency, in addition to USD 34.2 million annually for CADTH.
◉This funding strengthens pharmaceutical hydrocolloid adoption.
◉Region is projected to grow at a notable CAGR.
◉Growth is fueled by rising food processing, pharmaceutical R&D, and drug delivery systems.
Saudi Arabia
◉Largest pharmaceutical market in MEA with 40+ registered factories covering 36% of domestic pharma needs.
◉Supported by Saudi Vision 2030, aiming to expand pharma and biotech.
2.4.4 United Arab Emirates
◉Pharma sector supported by Abu Dhabi Industrial Strategy, with AED 10 billion investment.
◉Strong government support positions UAE as a biotech innovation hub in the region.
◉Rising Usage in Dermatology
◉Hydrocolloid dressings (HDs) are widely used for acute and chronic wound healing.
◉Applications include surgical wounds, donor graft sites, burns, and superficial injuries.
◉Hydrocolloids are increasingly used in acne patches, broadening their role from medical wound care to consumer skincare markets.
◉Strict Regulations
◉Hydrocolloid usage faces non-uniform global regulations.
◉Each region enforces different rules, raising production costs for region-specific compliance.
◉Food applications are especially affected, since hydrocolloid quantity limits vary across countries, restricting market expansion.
◉Rising Demand in Pharmaceuticals and Cosmetics
◉Hydrocolloids are gaining traction due to moisture retention, biocompatibility, and controlled release capabilities.
◉Used as excipients in tablets.
◉Found in wound care and hydrogel patches.
◉Enable controlled drug release.
◉Preferred in anti-aging and moisturizing formulas.
◉Serve as natural texturizers and stabilizers for skincare products.
◉Rising consumer interest in clean-label natural cosmetics supports growth.
1.1 Products → Supplies organic acids, amino acids, and hydrocolloids used in food & beverage, personal care, biodegradable plastics, and pharmaceuticals.
1.2 Overview → An American multinational chemical company with global leadership in specialty materials and advanced chemicals.
1.3 Strengths →
1.3.1 Diversified portfolio across nutrition, health, and industrial markets.
1.3.2 Strong financials with net sales of $3.1 billion in Q4 2024 and $12.4 billion for full year 2024.
1.3.3 Global supply chain strength, ensuring market dominance in regulated sectors like pharma and food.
2.1 Products → Specializes in taste & nutrition solutions, including clean-label hydrocolloids, stabilizers, and emulsifiers.
2.2 Overview → An Irish multinational focused on food, beverage, and nutrition markets.
2.3 Strengths →
2.3.1 Revenue leadership with €8.0 billion total revenue in 2024.
2.3.2 EBITDA growth of 7.4% in 2024, reaching €1,251 million.
2.3.3 Strong presence in North America, Europe, and APMEA, driven by nutritional innovation and reformulation trends.
3.1 Products → Offers hydrocolloids, polymers, and biopolymers for food, pharma, and personal care applications.
3.2 Overview → German multinational, one of the largest chemical producers globally.
3.3 Strengths →
3.3.1 Extensive R&D resources for next-gen hydrocolloids.
3.3.2 Global industrial processing scale, ensuring consistent quality and supply.
3.3.3 Strategic focus on sustainable chemical production.
4.1 Products → Supplies cellulose derivatives, guar-based thickeners, and hydrocolloid stabilizers for personal care, pharma, and industrial use.
4.2 Overview → A U.S.-based specialty chemicals company, widely known in regulated industries.
4.3 Strengths →
4.3.1 Strong regulatory compliance, making it reliable for pharma and cosmetics.
4.3.2 Expertise in controlled-release pharma applications.
4.3.3 Broad adoption in cosmetics and personal care markets.
5.1 Products → Offers pectin, xanthan gum, carrageenan, gellan gum for clean-label food & beverage, and personal care.
5.2 Overview → Specialist hydrocolloid producer focusing on plant- and algae-derived ingredients.
5.3 Strengths →
5.3.1 Leadership in clean-label solutions, catering to rising consumer demand.
5.3.2 Strong expertise in texture, stability, and plant-based formulations.
5.3.3 Global customer base in both food and pharma sectors.
6.1 Products → Produces gums, starches, pectins, and hydrocolloids for food, pharma, and cosmetics.
6.2 Overview → A U.S.-based agribusiness giant, one of the largest privately held companies in the world.
6.3 Strengths →
6.3.1 Vertically integrated sourcing ensures raw material security.
6.3.2 Massive global distribution network, guaranteeing supply reliability.
6.3.3 Strong positioning in commodity and specialty ingredients markets.
7.1 Products → Specializes in stabilizers, pectins, gums, and texture solutions.
7.2 Overview → UK-based global provider of food & beverage solutions.
7.3 Strengths →
7.3.1 Deep formulation expertise for consumer-packaged goods.
7.3.2 Strong ties with major food & beverage brands.
7.3.3 Active in sugar reduction and texture optimization trends.
8.1 Products → Supplies nutritional blends, proteins, and hydrocolloids for sports and wellness applications.
8.2 Overview → Irish company, focused on nutrition markets.
8.3 Strengths →
8.3.1 Strong presence in sports and performance nutrition.
8.3.2 Specialized in custom ingredient solutions.
8.3.3 Recognized for innovative blends and formulations.
9.1 Products → Focuses on gelatin, collagen, and animal-derived hydrocolloids.
9.2 Overview → U.S.-based sustainable ingredients company, converting waste into value-added products.
9.3 Strengths →
9.3.1 Circular economy model, turning by-products into revenue streams.
9.3.2 Leadership in collagen & gelatin market.
9.3.3 Strong alignment with sustainability and waste-to-value trends.
10.1 Products → Develops biotech-driven hydrocolloids, nutrition, and specialty ingredients.
10.2 Overview → Dutch multinational with focus on health, nutrition, and biosciences.
10.3 Strengths →
10.3.1 Strong biotech capabilities for innovation.
10.3.2 Global reputation in sustainability and regulatory compliance.
10.3.3 Leader in pharma and health nutrition hydrocolloids.
11.1 Products → Produces gums, starches, and other hydrocolloid ingredients.
11.2 Overview → American multinational and one of the world’s largest agricultural processors.
11.3 Strengths →
11.3.1 Global sourcing and supply chain capacity.
11.3.2 Massive investment power in innovation and expansion.
11.3.3 Broad customer base across food, pharma, and industrial applications.
1.1 A new biotech-driven initiative was announced, focusing on animal-free substitutes for traditional hydrocolloids.
1.2 The initiative leverages the GELITA Pharma Institute and the Biotech R&D Hub in Frankfurt.
1.3 Main goal → Create sustainable, resource-efficient, and improved-quality hydrocolloids compared to traditional animal-based gelatin.
1.4 Key Impact → Opens markets for halal, kosher, and vegan products, while strengthening pharma applications.
2.1 Bonyf NV (Germany) advanced to Phase 3 of its Alginate-Organic Olive Oil-based Denture Fixative Cream.
2.2 The approval followed a successful clinical-dermatological study by Dermatest GmbH.
2.3 Main Highlight → Demonstrates the pharmaceutical application of alginate hydrocolloids in oral care.
2.4 Jungbunzlauer invested $200 million to expand its facility in Port Colborne, Ontario, Canada.
2.5 This marks the establishment of Canada’s first xanthan gum factory.
2.6 Main Highlight → Strengthens North American supply chain for xanthan gum, used in food, cosmetics, and pharma.
1.1 Gelatin
1.1.1 Derived from animal collagen, widely used in confectionery, dairy, and pharmaceuticals.
1.1.2 Strength lies in gelling, stabilizing, and texturizing properties.
1.1.3 Growing demand from nutraceuticals and collagen supplements.
1.2 Carrageenan
1.2.1 Extracted from red seaweed, mainly used in dairy, meat processing, and beverages.
1.2.2 Acts as a stabilizer and thickener.
1.2.3 Key demand driver → plant-based, clean-label, vegan-friendly applications.
1.3 Xanthan Gum
1.3.1 Microbial polysaccharide used in beverages, sauces, dressings, and pharma.
1.3.2 Known for high stability in acidic and hot environments.
1.3.3 Expanding demand in gluten-free bakery formulations.
1.4 Alginates
1.4.1 Seaweed-derived, applied in pharma (wound dressings, dental creams), and food (ice creams, desserts).
1.4.2 Unique gel-forming ability even at low concentrations.
1.4.3 Bonyf NV’s alginate-olive oil denture cream Phase 3 (2025) highlights its pharma importance.
1.5 Pectin
1.5.1 Extracted from citrus peel and apple pomace.
1.5.2 Used in jams, jellies, fruit beverages, and dietary supplements.
1.5.3 Clean-label and natural source make it attractive for modern consumers.
1.6 Other Hydrocolloids (Guar Gum, Gellan Gum, Locust Bean Gum, etc.)
1.6.1 Widely applied in texture modification, thickening, and stability improvement.
1.6.2 Key driver → increasing demand for plant-based food formulations.
2.1 Thickening Agents
2.1.1 Essential in soups, sauces, dairy, and beverages.
2.1.2 Enhance mouthfeel and texture uniformity.
2.2 Stabilizers
2.2.1 Prevent phase separation in yogurt, beverages, ice cream.
2.2.2 Ensure shelf-life stability.
2.3 Gelling Agents
2.3.1 Provide structural integrity in confectionery, gummies, bakery fillings.
2.3.2 Enable vegan gel systems (carrageenan, agar).
2.4 Fat Replacers
2.4.1 Used in low-fat and diet products.
2.4.2 Offer creamy texture without calories of fats.
2.5 Coating Materials
2.5.1 Applied in confectionery, fruit preservation, pharma capsules.
2.5.2 Provide moisture resistance and controlled release.
2.6 Others (Binders, Emulsifiers, Controlled Release Agents)
2.6.1 Important for pharma drug delivery, personal care.
2.6.2 Expanding role in cosmetic formulations.
3.1 Food & Beverages (Largest Segment)
3.1.1 Covers bakery, confectionery, dairy, beverages, meat processing, sauces, dressings.
3.1.2 Growth driver → clean-label demand, vegan food, gluten-free bakery.
3.2 Pharmaceuticals
3.2.1 Hydrocolloids act as drug stabilizers, controlled-release excipients, and wound-care materials.
3.2.2 Bonyf NV (2025) highlights alginate’s relevance in oral care pharma.
3.3 Personal Care & Cosmetics
3.3.1 Used in lotions, creams, toothpaste, shampoos.
3.3.2 Act as texture enhancers, stabilizers, and emulsifiers.
3.4 Industrial Applications
3.4.1 Includes paper, textiles, oil drilling fluids, biodegradable packaging.
3.4.2 Hydrocolloids support sustainability and bio-based material demand.
4.1 North America
4.1.1 Major market driven by processed foods and pharma demand.
4.1.2 Jungbunzlauer’s $200M xanthan gum facility (Canada, 2024) strengthens local supply.
4.2 Europe
4.2.1 Driven by clean-label food, strict EU food safety regulations.
4.2.2 Home to DSM, Kerry, BASF, Jungbunzlauer.
4.3 Asia-Pacific (APAC)
4.3.1 Fastest-growing, fueled by China, India, Japan.
4.3.2 Plant-based diets, personal care boom, pharma expansion drive growth.
4.4 Latin America
4.4.1 Major raw material source (seaweed, guar).
4.4.2 Strong growth in carrageenan and gelatin exports.
4.5 Middle East & Africa
4.5.1 Smaller but growing demand due to halal & kosher food markets.
4.5.2 Biotech-driven animal-free hydrocolloids (2025) will be key enablers.
1.1 Hydrocolloids are water-loving polymers (natural or synthetic) used to control texture, viscosity, and stability in food, pharma, and personal care.
1.2 They are critical because they replace fats, stabilize products, extend shelf life, and enable vegan-friendly formulations.
2.1 Gelatin dominates due to its strong presence in confectionery, pharma capsules, and nutraceuticals.
2.2 However, pectin, xanthan gum, and carrageenan are rapidly growing because of plant-based and clean-label consumer demand.
3.1 Sustainability trends are pushing companies to develop animal-free, biotech-driven hydrocolloids (e.g., January 2025 announcement).
3.2 Pharmaceutical applications (alginate denture cream, 2025) highlight diversification.
3.3 Clean-label food demand is pushing natural sources like pectin and guar gum.
4.1 North America and Europe lead in market share due to processed food demand, strong pharma industries, and clean-label adoption.
4.2 Asia-Pacific is the fastest-growing region with rapid expansion in food, pharma, and personal care consumption.
5.1 January 2025 → Biotech-driven animal-free hydrocolloids initiative.
5.2 April 2025 → Bonyf NV alginate-based denture fixative cream advanced to Phase 3.
5.3 September 2024 → Jungbunzlauer invested $200M in Canada’s first xanthan gum factory.
Access our exclusive, data-rich dashboard dedicated to the healthcare market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/price/5592
Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
Web: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
The global nootropics market size reached USD 5.71 billion in 2025 and is projected to grow to USD 19.53 billion… Read More
The U.S. concierge medicine market was valued at USD 7.25 billion in 2024, grew to USD 8 billion in 2025,… Read More
The global recombinant proteins market is valued at USD 3.36 billion in 2025 and projected to reach USD 8.08 billion… Read More
The global digital biomarkers market was valued at USD 5.09 billion in 2025 and is projected to reach USD 32.37… Read More
The global chemotherapy market is estimated at USD 10.28 billion in 2025 and projected to reach USD 19.35 billion by… Read More
The global endoscopy devices market was valued at USD 61.1 billion in 2024, increased to USD 63.44 billion in 2025,… Read More